# China Recombinant Proteins Market

> China Recombinant Proteins Market Research Report By Product (Hormones, Growth Factors, Antibody, Enzymes, Other Types of Products) and By Application (Research Applications, Therapeutic Use, Biotechnology Industry) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.0%
- **2024:** $ 277.15 Million
- **2025:** $ 299.32 Million
- **2035:** $ 646.35 Million
- **Key Players:** Amgen (US), Genentech (US), Roche (CH), Bristol-Myers Squibb (US), Merck KGaA (DE), Novartis (CH), Sanofi (FR), Pfizer (US), Eli Lilly (US)

**Report ID:** MRFR/LS/48743-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/china-recombinant-proteins-market-50500

---

## Market Summary

## **China Recombinant Proteins Market Overview**

As per MRFR analysis, the China Recombinant Proteins Market Size was estimated at 256.3 (USD Million) in 2023. The China Recombinant Proteins Market Industry is expected to grow from 276.8(USD Million) in 2024 to 1,760.7 (USD Million) by 2035. The China Recombinant Proteins Market CAGR (growth rate) is expected to be around 18.317% during the forecast period (2025 - 2035)

**Key China Recombinant Proteins Market Trends Highlighted**

There has been substantial improvement in the Recombinant Proteins Market in China due to the biotechnological advancements, as well as devoted R&D efforts. Moreover, the Chinese government has implemented many initiatives to support innovation in biopharmaceuticals and increase investment in producing recombinant protein. Additionally, the supply of these proteins for various therapeutic uses such as cancer and diabetes treatment is increasing. Furthermore, there remain high untapped market possibilities in personalized medicine and biosimilars. Increasing population, chronic diseases, and aging require more effective therapeutic proteins.

Chinese domestic firms are progressing toward the innovative recombinant proteins’ construction due to the country’s self-reliance policies on biopharmaceuticals, thereby reducing the dependency on imports and enhancing their market stance. There are recent moves indicating an increasing trend of contracting new recombinant proteins development to academic institutions in collaboration with biotech firms. It is also important to note the rise of contract manufacturing organizations in China that provide tailored assistance to help local companies scale up production. Furthermore, the integration of artificial intelligence and automation into manufacturing processes is streamlining the production of recombinant proteins.

Cumulatively, the developments showcase the ever-evolving China recombined proteins market and their increasing position in the global biopharmaceuticals market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**China Recombinant Proteins Market Drivers**

**Increasing Demand for Biopharmaceuticals**

The China Recombinant Proteins Market Industry is experiencing significant growth due to the increasing demand for biopharmaceuticals. With the rise in chronic diseases, particularly diabetes and cancer, there is a pressing need for effective therapeutic solutions. According to data from the National Health Commission of China, the number of diabetes cases in China reached approximately 120 million in 2021, reflecting a worrying trend. 

The Chinese government has been actively promoting innovation in the biopharmaceutical sector as part of its 13th Five-Year Plan for Health, which further supports the growth of recombinant proteins in therapeutics.Major biopharmaceutical companies like China National Pharmaceutical Group Corporation are investing heavily in the Research and Development (R&D) of recombinant protein drugs, indicating an optimistic outlook for this sector. Thus, the rising patient population and supportive governmental policies create a fertile ground for the China Recombinant Proteins Market Industry.

**Advancements in Genetic Engineering and Biotechnology**

Technological advancements in genetic engineering and biotechnology are significantly driving the growth of the China Recombinant Proteins Market Industry. The biotechnology industry is witnessing faster breakthroughs in gene editing technologies, such as CRISPR-Cas9, enhancing the production and effectiveness of recombinant proteins. Research outputs from leading Chinese universities and institutions signify that over 150 patents were filed related to genetic engineering techniques in the past two years, reflecting innovation in this field.

Organizations such as the Chinese Academy of Sciences are focusing on cutting-edge research that improves protein expression systems, thus streamlining recombinant protein manufacture. This increased technological capability not only boosts production efficiency but also enhances product safety and efficacy, thereby attracting investment and fostering market growth.

**Supportive Regulatory Environment**

The regulatory environment in China is becoming increasingly supportive of the recombinant proteins sector. The introduction of new policies and guidelines by the National Medical Products Administration (NMPA) simplifies the approval process for recombinant proteins, which encourages innovation and market entry for new products. For instance, the NMPA launched an expedited review process that can reduce the approval timeline by up to 60%, allowing products to reach the market faster.This change is enhancing the potential for successful launches of novel recombinant therapies.

As a result, market players operating within the China Recombinant Proteins Market Industry are better positioned to capitalize on opportunities arising from the growing demand for biologics, ultimately expediting their growth and expansion.

**Rising Investment in Healthcare Infrastructure**

China’s rising investment in healthcare infrastructure is another critical driver for the China Recombinant Proteins Market Industry. With the healthcare spending projected to rise and reach 7% of Gross Domestic Product (GDP) by 2025, the government aims to enhance access to healthcare services across the nation. As part of the Healthy China initiative, investment in biotechnology and pharmaceutical sectors is prioritized, ensuring that cutting-edge therapeutics like recombinant proteins are developed and distributed effectively.

This aligns with the strategic focus of organizations like the National Health Commission of China, which emphasizes improving public health outcomes. Therefore, the improved healthcare infrastructure paves the way for broader availability of advanced therapeutics, generating increasing demand for recombinant proteins in China.

**China Recombinant Proteins Market Segment Insights**

**Recombinant Proteins Market Product Insights**

The China Recombinant Proteins Market is showcasing a dynamic landscape characterized by diverse products tailored for varied applications in the field of biotechnology and pharmaceuticals. Within this framework, hormones represent a critical segment as they play a significant role in therapeutic applications, particularly in treating hormonal deficiencies and disorders. 

The demand for growth factors is soaring, primarily due to their pivotal function in cell growth, development, and repair, which is especially relevant in regenerative medicine and cancer treatments.Antibodies, particularly monoclonal antibodies, are at the forefront of the Recombinant Proteins Market, revolutionizing cancer therapy and autoimmune disease treatments. 

This segment is anticipated to continue its dominance owing to ongoing innovations and enhanced specificity in therapeutic applications. Enzymes also contribute significantly to the market, serving diverse functions in diagnostics and bioprocessing, making them vital for various industrial applications including food and pharmaceuticals. Other types of products within the Recombinant Proteins 

Market enhance the market's segmentation, catering to niche applications that may require specialized proteins.The robust growth of the China Recombinant Proteins Market is driven by increasing healthcare expenditures and the rising prevalence of chronic diseases necessitating advanced therapeutic solutions. 

Moreover, supportive governmental policies and investments aimed at bolstering the biotechnology sector present extensive opportunities for growth across all segments, enabling enhanced research and development efforts. As the market continues to evolve, trends such as personalized medicine and advancements in genetically engineered proteins are set to further redefine the landscape, presenting both challenges and significant opportunities for stakeholders involved in the China Recombinant Proteins Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Recombinant Proteins Market Application Insights**

The Application segment of the China Recombinant Proteins Market plays a critical role in the growth and development of various health and scientific sectors. Research Applications are vital for advancing scientific inquiry, as they support a wide array of studies from drug discovery to protein interactions. Therapeutic Use is increasingly significant as it encompasses the development of treatments for chronic diseases and genetic disorders, contributing to improved patient outcomes and enhanced healthcare quality. 

Furthermore, the Biotechnology Industry continually evolves, utilizing recombinant proteins to develop innovative solutions, such as biosimilars and personalized medicine.The increasing investment in biotechnology and healthcare infrastructure in China fuels the growth of these applications, paving the way for improved technologies and health solutions. With a focus on innovation, the Application segment stands out as a key driver in the expansion of the China Recombinant Proteins Market, reflecting the nation’s commitment to enhancing health and biotechnology advancements in the region. 

Overall, the dynamics within this segment underscore its importance in addressing global health challenges while catalyzing sustainable market growth.

**China Recombinant Proteins Market Key Players and Competitive Insights**

The China Recombinant Proteins Market has shown significant growth and development, characterized by an increasingly competitive landscape. As the market is expected to expand due to rising demand in various applications such as therapeutics, diagnostics, research, and development, several key players are vying for market share. The competitive insights reveal a trend towards innovation, with companies focusing on advanced biotechnological techniques to enhance the efficiency and efficacy of recombinant proteins. This sector is marked by strategic collaborations, mergers, and acquisitions aimed at strengthening market presence and expanding product portfolios. 

The focus on quality, regulatory compliance, and distribution capabilities also plays a crucial role in determining the competitive positioning of companies within the market.Shanghai Junshi Biosciences has established itself as a formidable player in the China Recombinant Proteins Market, leveraging strong expertise in biotechnology and research to develop a range of innovative products. The company's focus on biosimilars and novel therapeutic proteins has helped it gain considerable traction in the market. 

With strong research and development capabilities, Shanghai Junshi Biosciences has successfully introduced several recombinant protein products, contributing to its reputation as a trusted provider in the biopharmaceutical domain. The company's emphasis on collaboration with research institutions and universities has facilitated the advancement of knowledge and technology, enabling the rapid development of next-generation recombinant protein therapies. Its strong presence in various therapeutic areas underscores its commitment to addressing the healthcare needs of the Chinese population.

Beijing Tiantan Biological Products is another key player in the China Recombinant Proteins Market known for its focus on vaccine development and biotechnology. The company has carved out a niche in the production of recombinant proteins specifically for vaccines and therapeutic applications. Its investment in research and development has allowed the introduction of numerous key products aimed at infectious diseases, enhancing public health frameworks in China. 

With a strong market presence backed by solid distribution networks, Beijing Tiantan Biological Products has strategically allied with other biotechnology firms and academic institutions to supplement its R&D efforts. The company’s partnerships and potential mergers in the biotechnology space reflect its ongoing commitment to growth and innovation in the recombinant proteins field, ensuring its competitive edge in a fast-evolving market landscape.

**Key Companies in the China Recombinant Proteins Market Include**

**China Recombinant Proteins Market Industry Developments**

Recent developments in the China Recombinant Proteins Market have been marked by significant activity and advancements. Shanghai Junshi Biosciences has expanded its portfolio with new therapeutic proteins targeting various diseases, while Beijing Tiantan Biological Products has launched a novel recombinant influenza vaccine, reflecting China's push for innovative healthcare solutions. Hualan Biological Engineering is also focusing on expanding its recombinant vaccine capabilities to meet rising domestic demand. In a noteworthy collaboration, WuXi AppTec has partnered with AbbVie to enhance Research and Development efforts in protein engineering. 

Additionally, GenScript has announced plans to increase its production capacity to cater to the growing global demand for recombinant proteins. Merger and acquisition activities have also been notable in recent months, with Roche acquiring a minority stake in a promising biotech firm in China as of September 2023, further solidifying its presence in the region. The market valuation of companies like Amgen and Merck KGaA has seen an upward trend, driven by increased investment in biotechnology sectors and support from China's government towards biotechnology innovation, inherently impacting the growth trajectory of the Recombinant Proteins Market in the region.

**China Recombinant Proteins Market Segmentation Insights**

## Market Drivers

### Strengthening Regulatory Frameworks

The evolving regulatory landscape in China is fostering growth in the recombinant proteins market. Recent reforms aimed at streamlining the approval process for biopharmaceuticals are likely to enhance the speed and efficiency of bringing new products to market. The National Medical Products Administration (NMPA) has implemented measures to facilitate faster reviews and approvals, which may encourage innovation in recombinant protein development. As a result, companies are more inclined to invest in research and development, knowing that regulatory hurdles are being addressed. This supportive environment is expected to drive the recombinant proteins market forward, as it allows for the timely introduction of novel therapies that meet the growing healthcare demands in China.

### Growing Prevalence of Chronic Diseases

The increasing incidence of chronic diseases in China is a critical driver for the recombinant proteins market. Conditions such as diabetes, cancer, and cardiovascular diseases are becoming more prevalent, necessitating innovative treatment options. The World Health Organization indicates that chronic diseases account for approximately 80% of all deaths in China, highlighting the urgent need for effective therapies. Recombinant proteins, known for their efficacy in treating various ailments, are likely to see heightened demand as healthcare providers seek advanced solutions. This trend is expected to propel the recombinant proteins market forward, as pharmaceutical companies focus on developing targeted therapies that leverage recombinant technology to address these health challenges.

### Rising Demand for Personalized Medicine

The shift towards personalized medicine is emerging as a significant driver for the recombinant proteins market in China. As healthcare becomes increasingly tailored to individual patient needs, the demand for specific therapeutic proteins is likely to rise. Personalized medicine aims to optimize treatment efficacy by considering genetic, environmental, and lifestyle factors. This trend is expected to create opportunities for recombinant proteins that can be customized for specific patient profiles. In 2025, the market for personalized medicine is projected to reach $50 billion, with recombinant proteins playing a crucial role in this transformation. The ability to develop targeted therapies that align with personalized treatment plans may enhance the overall effectiveness of healthcare delivery in China.

### Increasing Investment in Biopharmaceuticals

The recombinant proteins market in China is experiencing a surge in investment, particularly in the biopharmaceutical sector. With the Chinese government prioritizing healthcare innovation, funding for research and development in recombinant proteins is on the rise. In 2025, the biopharmaceutical industry is projected to reach a market value of approximately $100 billion, with recombinant proteins playing a pivotal role. This influx of capital is likely to enhance the capabilities of local companies, enabling them to develop novel therapeutic proteins. Furthermore, collaborations between academic institutions and industry players are fostering innovation, which may lead to breakthroughs in drug development. As a result, the recombinant proteins market is expected to expand significantly, driven by these investments and the growing emphasis on advanced therapeutic solutions.

### Technological Advancements in Protein Engineering

Technological innovations in protein engineering are significantly impacting the recombinant proteins market in China. Advances in genetic engineering techniques, such as CRISPR and synthetic biology, are enabling researchers to design and produce more effective recombinant proteins. These technologies facilitate the creation of proteins with enhanced therapeutic properties, which may lead to improved patient outcomes. In 2025, the market for recombinant proteins is anticipated to grow at a CAGR of around 10%, driven by these advancements. As companies adopt cutting-edge technologies, the efficiency and cost-effectiveness of protein production are likely to improve, further stimulating market growth. This dynamic environment suggests a promising future for the recombinant proteins market as it adapts to the evolving landscape of biotechnology.

## Future Outlook

The [Recombinant Proteins Market](https://www.marketresearchfuture.com/reports/recombinant-proteins-market-21550) in China is projected to grow at an 8.0% CAGR from 2025 to 2035, driven by advancements in biotechnology and increasing demand for therapeutic proteins.

**New opportunities:**

- Development of personalized recombinant protein therapies for niche markets.
- Expansion of recombinant protein production facilities to enhance capacity.
- Strategic partnerships with biotech firms for innovative product development.

By 2035, the recombinant proteins market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Product: Antibody (Largest) vs. Enzymes (Fastest-Growing)

In the China recombinant proteins market, the distribution of market share among product segments is led by antibodies, which take the largest portion due to their extensive application in therapeutic and diagnostic fields. Following antibodies, hormones and growth factors play significant roles, while enzymes and other types of products contribute to a smaller yet essential share.

Growth trends in the product segment indicate a robust expansion, particularly for enzymes, which are recognized as the fastest-growing category. The increasing demand for biopharmaceuticals, advancements in genetic engineering, and the growing prevalence of chronic diseases are driving forces behind this growth. The rising investments in research and development also create opportunities for emerging protein products, paving the way for innovation and market diversification.

Hormones (Dominant) vs. Other Types of Products (Emerging)

Hormones remain a dominant product type in the China recombinant proteins market, primarily due to their crucial roles in therapeutic applications, including diabetes and growth disorders. They are widely recognized for their therapeutic potency and are backed by established market players with extensive portfolios. In contrast, other types of products, while currently considered emerging, are gaining traction as research into novel proteins and their applications progresses. These products often cater to niche markets and are bolstered by innovations in biotechnology and an increasing focus on personalized medicine, representing a promising future in the sector.

### By Application: Therapeutic Use (Largest) vs. Research Application (Fastest-Growing)

In the China recombinant proteins market, the distribution of market share is primarily dominated by the therapeutic use segment, which caters to a growing demand for novel treatments. This segment has established itself as the most significant contributor to the market, driven by advancements in healthcare and increasing investments in biopharmaceuticals. In contrast, the research application segment is experiencing rapid growth as more organizations engage in innovative research activities that leverage recombinant protein technologies, although it currently holds a smaller portion of the overall market share.

The growth trends within the application segment are largely influenced by the rising prevalence of chronic diseases in the region, along with the demand for targeted therapies. Moreover, governmental initiatives to promote research and development in biotechnology have bolstered the research application sector, making it an exciting area to watch. The synergy between therapeutic developments and research applications is likely to propel the market further, offering opportunities for companies to diversify their portfolios and engage in groundbreaking discoveries.

Therapeutic Use (Dominant) vs. Research Application (Emerging)

The therapeutic use segment has emerged as the dominant force within the application segment of the China recombinant proteins market, characterized by its vast array of applications in treating diseases such as diabetes, cancer, and autoimmune disorders. This segment benefits from substantial investments in drug development and a strong pipeline of innovative therapies. Conversely, the research application segment is seen as an emerging area, with increasing adoption of recombinant proteins for academic and clinical research purposes. This growth is attributed to the need for high-quality reagents and tools in fundamental research and drug discovery. As the emphasis on biotech research intensifies, this segment is poised for significant growth, presenting a dual paradigm of established therapeutic solutions and innovative research applications.

## Competitive Benchmarking

The recombinant proteins market in China is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on regional expansion. Key players such as Amgen (US), Genentech (US), and Roche (CH) are actively shaping the market through their distinct operational strategies. Amgen (US) emphasizes innovation in biopharmaceuticals, particularly in oncology and cardiovascular diseases, while Genentech (US) focuses on personalized medicine and targeted therapies. Roche (CH) leverages its extensive research capabilities to enhance its product pipeline, particularly in diagnostics and therapeutics, thereby reinforcing its market position. Collectively, these strategies contribute to a competitive environment that is increasingly focused on advanced therapeutic solutions and patient-centric approaches.In terms of business tactics, companies are localizing manufacturing to reduce costs and enhance supply chain efficiency. This approach is particularly relevant in a moderately fragmented market where multiple players vie for market share. The collective influence of these key players fosters a competitive structure that encourages innovation and responsiveness to market demands, ultimately benefiting consumers through improved access to advanced therapies.

In October  Roche (CH) announced a strategic partnership with a leading Chinese biotechnology firm to co-develop a novel recombinant protein therapy aimed at treating autoimmune diseases. This collaboration is significant as it not only enhances Roche's local presence but also accelerates the development of therapies tailored to the specific needs of the Chinese population. Such partnerships are indicative of a broader trend where multinational corporations seek to leverage local expertise to navigate regulatory landscapes and market dynamics effectively.

In September  Amgen (US) launched a new recombinant protein product specifically designed for the treatment of rare genetic disorders. This launch is pivotal as it underscores Amgen's commitment to addressing unmet medical needs in China, a market with a growing demand for specialized therapies. The introduction of this product is expected to strengthen Amgen's foothold in the region and enhance its competitive edge against local and international rivals.

In November  Genentech (US) unveiled a digital platform aimed at streamlining the distribution of its recombinant protein therapies across China. This initiative reflects a growing trend towards digital transformation within the industry, as companies seek to optimize their supply chains and improve patient access to therapies. By integrating technology into its operations, Genentech positions itself as a forward-thinking leader in the market, likely enhancing its operational efficiency and customer engagement.

As of November  current competitive trends in the recombinant proteins market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and enhancing market reach. Looking ahead, competitive differentiation is expected to evolve, with a notable shift from price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This transition may ultimately lead to a more sustainable and patient-centric market environment.

## Recent News & Developments

Recent developments in the China Recombinant Proteins Market have been marked by significant activity and advancements. Shanghai Junshi Biosciences has expanded its portfolio with new therapeutic proteins targeting various diseases, while Beijing Tiantan Biological Products has launched a novel recombinant influenza vaccine, reflecting China's push for innovative healthcare solutions. Hualan Biological Engineering is also focusing on expanding its recombinant vaccine capabilities to meet rising domestic demand. In a noteworthy collaboration, WuXi AppTec has partnered with AbbVie to enhance Research and Development efforts in protein engineering. 

Additionally, GenScript has announced plans to increase its production capacity to cater to the growing global demand for recombinant proteins. Merger and acquisition activities have also been notable in recent months, with Roche acquiring a minority stake in a promising biotech firm in China as of September 2023, further solidifying its presence in the region. The market valuation of companies like Amgen and Merck KGaA has seen an upward trend, driven by increased investment in biotechnology sectors and support from China's government towards biotechnology innovation, inherently impacting the growth trajectory of the Recombinant Proteins Market in the region.

## Report Scope

| MARKET SIZE 2024 | 277.15(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 299.32(USD Million) |
| MARKET SIZE 2035 | 646.35(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.0% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Amgen (US), Genentech (US), Roche (CH), Bristol-Myers Squibb (US), Merck KGaA (DE), Novartis (CH), Sanofi (FR), Pfizer (US), Eli Lilly (US) |
| Segments Covered | Product, Application |
| Key Market Opportunities | Advancements in gene editing technologies enhance production efficiency in the recombinant proteins market. |
| Key Market Dynamics | Rising demand for therapeutic recombinant proteins drives innovation and competition among local and global manufacturers. |
| Countries Covered | China |

## Frequently Asked Questions

**Q: What was the overall market valuation of the recombinant proteins market in 2024?**
A: The overall market valuation was $277.15 Million in 2024.

**Q: What is the projected market valuation for the recombinant proteins market by 2035?**
A: The projected valuation for 2035 is $646.35 Million.

**Q: What is the expected CAGR for the recombinant proteins market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period is 8.0%.

**Q: Which companies are considered key players in the recombinant proteins market?**
A: Key players include Amgen, Genentech, Roche, Bristol-Myers Squibb, Merck KGaA, Novartis, Sanofi, Pfizer, and Eli Lilly.

**Q: What were the revenue figures for the antibody segment in 2024?**
A: The antibody segment generated revenues between $90.0 Million and $220.0 Million in 2024.

**Q: How did the therapeutic use application perform in 2024?**
A: The therapeutic use application had a revenue range of $150.0 Million to $350.0 Million in 2024.

**Q: What is the revenue range for growth factors in the recombinant proteins market?**
A: The revenue range for growth factors was between $50.0 Million and $120.0 Million in 2024.

**Q: What segment had the lowest revenue in 2024?**
A: The segment categorized as 'Other Types of Products' had the lowest revenue, ranging from $37.15 Million to $56.35 Million in 2024.

**Q: What is the revenue range for enzymes in the recombinant proteins market?**
A: The enzymes segment reported revenues between $60.0 Million and $150.0 Million in 2024.

**Q: What was the revenue for research applications in 2024?**
A: The research application segment generated revenues between $55.43 Million and $130.0 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-recombinant-proteins-market-50500*